Literature DB >> 32619300

Proteomic and Genomic Methylation Signatures of Idiopathic Subglottic Stenosis.

Stephen S Schoeff1, Xudong Shi1, William G Young1, Chad W Whited1, Resha S Soni1, Peng Liu2, Irene M Ong2,3, Seth H Dailey1, Nathan V Welham1.   

Abstract

OBJECTIVE: Idiopathic subglottic stenosis (iSGS) is a chronic inflammatory condition that causes dyspnea and affects middle-aged women of White race and non-Latino or Hispanic ethnicity. To better characterize its phenotype and pathogenesis, we assessed the proteomic and genomic methylation signatures of subglottic tissue collected from iSGS patients compared to controls. STUDY
DESIGN: Molecular analysis of clinical biospecimens.
METHODS: We collected subglottic tissue biopsies from 12 patients during direct laryngoscopy, immediately prior to surgical treatment of iSGS; as well as from 4 age-, sex-, and race/ethnicity-matched control patients undergoing other direct laryngoscopic procedures. We isolated protein and genomic DNA, acquired proteomic data using label-free quantitative mass spectrometry techniques, and acquired genome-wide methylation data using bisulfite conversion and a microarray platform. We compared molecular profiles across the iSGS and control groups, and with respect to clinical course in the iSGS group. Eight of the 12 iSGS patients underwent subsequent blood collection and plasma isolation for further assessment.
RESULTS: Proteomic analysis revealed 42 differentially abundant proteins in the iSGS biopsies compared to controls, inferring enrichment of biological pathways associated with early wound healing, innate immunity, matrix remodeling, and metabolism. Proteome-based hierarchical clustering organized patients into two iSGS and one control subgroups. Methylation analysis revealed five hypermethylated genes in the iSGS biopsies compared to controls, including the biotin recycling enzyme biotinidase (BTD). Follow-up analysis showed elevated plasma BTD activity in iSGS patients compared to both controls and published normative data.
CONCLUSION: iSGS exhibits distinct proteomic and genomic methylation signatures. These signatures expand current understanding of the iSGS phenotype, support the possibility of disease subgroups, and should inform the direction of future experimental studies. LEVEL OF EVIDENCE: Not applicable Laryngoscope, 131:E540-E546, 2021.
© 2020 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Biotin, biotinidase, dyspnea, fibrosis, inflammation, metabolism, 'omics, stenosis

Mesh:

Substances:

Year:  2020        PMID: 32619300      PMCID: PMC7779687          DOI: 10.1002/lary.28851

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  59 in total

1.  Elevated serum biotinidase activity in hepatic glycogen storage disorders--a convenient biomarker.

Authors:  P Paesold-Burda; M R Baumgartner; R Santer; N U Bosshard; B Steinmann
Journal:  J Inherit Metab Dis       Date:  2007-11-12       Impact factor: 4.982

2.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.

Authors:  Jürgen Cox; Matthias Mann
Journal:  Nat Biotechnol       Date:  2008-11-30       Impact factor: 54.908

3.  Dynamic changes of DNA methylation and lung disease in cystic fibrosis: lessons from a monogenic disease.

Authors:  Milena Magalhães; Jörg Tost; Fanny Pineau; Isabelle Rivals; Florence Busato; Nathan Alary; Laurent Mely; Sylvie Leroy; Marlène Murris; Davide Caimmi; Mireille Claustres; Raphaël Chiron; Albertina De Sario
Journal:  Epigenomics       Date:  2018-07-27       Impact factor: 4.778

4.  Serial office-based steroid injections for treatment of idiopathic subglottic stenosis.

Authors:  Matthew R Hoffman; Adam R Coughlin; Seth H Dailey
Journal:  Laryngoscope       Date:  2017-06-05       Impact factor: 3.325

5.  Role of balloon dilation in the management of adult idiopathic subglottic stenosis.

Authors:  Kenneth H Lee; Michael J Rutter
Journal:  Ann Otol Rhinol Laryngol       Date:  2008-02       Impact factor: 1.547

6.  Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency.

Authors:  B Wolf; R E Grier; R J Allen; S I Goodman; C L Kien
Journal:  Clin Chim Acta       Date:  1983-07-15       Impact factor: 3.786

7.  Adult idiopathic subglottic stenosis: a diagnostic and therapeutic challenge.

Authors:  Giovanni Garini; Luigi Fecci; Roberto Giacosa; Augusto Vaglio
Journal:  Ann Ital Med Int       Date:  2004 Jan-Mar

8.  Increased platelet reactivity in idiopathic pulmonary fibrosis is mediated by a plasma factor.

Authors:  Michael G Crooks; Ahmed Fahim; Khalid M Naseem; Alyn H Morice; Simon P Hart
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

9.  Molecular analysis of idiopathic subglottic stenosis for Mycobacterium species.

Authors:  Alexander Gelbard; Nicolas-George Katsantonis; Masanobu Mizuta; Dawn Newcomb; Joseph Rotsinger; Bernard Rousseau; James J Daniero; Eric S Edell; Dale C Ekbom; Jan L Kasperbauer; Alexander T Hillel; Liying Yang; C Gaelyn Garrett; James L Netterville; Christopher T Wootten; David O Francis; Charles Stratton; Kevin Jenkins; Tracy L McGregor; Jennifer A Gaddy; Timothy S Blackwell; Wonder P Drake
Journal:  Laryngoscope       Date:  2016-06-14       Impact factor: 3.325

Review 10.  Epigenetic reprogramming in liver fibrosis and cancer.

Authors:  Caroline L Wilson; Derek A Mann; Lee A Borthwick
Journal:  Adv Drug Deliv Rev       Date:  2017-10-25       Impact factor: 15.470

View more
  2 in total

1.  Prevalence and incidence of idiopathic subglottic stenosis in southern and central Alberta: a retrospective cohort study.

Authors:  Ryan K Chan; Beau Ahrens; Paul MacEachern; J Douglas Bosch; Derrick R Randall
Journal:  J Otolaryngol Head Neck Surg       Date:  2021-11-12

Review 2.  An Updated Review of Subglottic Stenosis: Etiology, Evaluation, and Management.

Authors:  Luke J Pasick; Mursalin M Anis; David E Rosow
Journal:  Curr Pulmonol Rep       Date:  2022-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.